|
| Press Releases |
|
 |
|
| Wednesday, September 8, 2021 |
|
|
阿诺医药宣布AN2025、AN0025与atezolizumab三联治疗晚期实体瘤1a期临床在美国完成首例患者给药 |
阿诺医药，一家专注于肿瘤治疗领域的创新型全球生物制药公司，今日宣布其口服泛PI3K抑制剂buparlisib（AN2025）、口服EP4拮抗剂（AN0025）与PD-L1抑制剂atezolizumab（阿替利珠单抗）三联疗法在晚期/转移性实体瘤患者中开展的Ia期临床试验已于美国成功完成首例患者给药。
more info >> |
|
|
阿諾醫藥宣佈AN2025、AN0025與atezolizumab三聯治療晚期實體瘤1a期臨床在美國完成首例患者給藥 |
| 阿諾醫藥，一家專注於腫瘤治療領域的創新型全球生物製藥公司，今日宣佈其口服泛PI3K抑制劑buparlisib（AN2025）、口服EP4拮抗劑（AN0025）與PD-L1抑制劑atezolizumab（阿替利珠單抗）三聯療法在晚期/轉移性實體瘤患者中開展的Ia期臨床試驗已于美國成功完成首例患者給藥。 more info >> |
|
|
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors |
| Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple combination of AN2025 (buparlisib, oral pan-PI3K inhibitor), AN0025 (oral EP4 antagonist) and atezolizumab (PD-L1 inhibitor) in patients with locally advanced/metastatic tumors. more info >> |
|
| Thursday, July 15, 2021 |
|
|
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures |
| Adlai Nortye Ltd. (hereinafter referred to as "Adlai Nortye"), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced the completion of $100 million Series D financing round. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
International Women's Day: Why Menopause May Be a Missed Cardiovascular Risk Window
Mar 6, 2026 20:00 JST
|
|
|
Xunce (3317.HK) Released Profit Alert: Revenue Doubles, Surpasses Expectations by a Wide Margin, China's Palantir Rises!
Mar 6, 2026 18:23 HKT/SGT
|
|
|
迅策(3317.HK)發佈盈利預告：營收翻翻 大超預期 中國版Palantir崛起！
Mar 6, 2026 18:17 HKT/SGT
|
|
|
迅策(3317.HK)发布盈利预告：营收翻翻 大超预期 中国版Palantir崛起！
Mar 6, 2026 18:00 HKT/SGT
|
|
|
香港實現綠色甲醇首船加注 推動國際航運中心綠色轉型
Mar 6, 2026 15:40 HKT/SGT
|
|
|
香港实现绿色甲醇首船加注 推动国际航运中心绿色转型
Mar 6, 2026 15:31 HKT/SGT
|
|
|
Hong Kong Completes First Green Methanol Bunkering, Driving Green Transformation of Its International Shipping Hub
Mar 6, 2026 15:05 HKT/SGT
|
|
|
Hong Kong Tech Innovators Drive Success at Mobile World Congress and 4YFN Barcelona 2026
Mar 6, 2026 13:08 HKT/SGT
|
|
|
U.S. Polo Assn. Expands Collegiate Partnership Program to Record 70 Teams for 2026 Season
Mar 6, 2026 12:12 HKT/SGT
|
|
|
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Mar 6, 2026 10:00 HKT/SGT
|
|
|
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 5, 2026 22:00 JST
|
|
|
美國馬球協會擴大大學合作計畫 2026賽季隊伍數創紀錄達70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
美国马球协会扩大大学合作计划，2026赛季参赛队伍创纪录达70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
Lancaster Resources Announces Resignation of Penny White and the Addition of Rob Heaslop to the Board of Directors
Mar 5, 2026 17:29 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Mar 5, 2026 17:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
